|
gptkbp:instanceOf
|
gptkb:drug
tumor necrosis factor inhibitor
|
|
gptkbp:administeredBy
|
gptkb:physician
self-injection
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L04AB01
|
|
gptkbp:biosimilar
|
gptkb:Benepali
gptkb:Erelzi
gptkb:Eticovo
|
|
gptkbp:brand
|
gptkb:Enbrel
|
|
gptkbp:CASNumber
|
gptkb:185243-69-0
|
|
gptkbp:contraindication
|
sepsis
|
|
gptkbp:developedBy
|
gptkb:Immunex
|
|
gptkbp:halfLife
|
3-5 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
etanercept
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
gptkb:Amgen
|
|
gptkbp:mechanismOfAction
|
inhibits TNF-alpha
|
|
gptkbp:molecularWeight
|
150 kDa
|
|
gptkbp:monitors
|
regular blood tests
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Crohn's_disease
ulcerative colitis
inflammatory bowel disease
|
|
gptkbp:patentExpired
|
2012 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults
children (with certain conditions)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:riskFactor
|
malignancy
autoimmune reactions
reactivation of latent tuberculosis
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
headache
injection site reaction
upper respiratory tract infection
increased risk of infection
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_beta
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:UNII
|
50PK0277D9
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:bfsParent
|
gptkb:Enbrel
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:bfsLayer
|
6
|